Drug · CHEMBL577294
2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN. Drugs and targets, record CHEMBL577294. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL577294
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Hpbcd, Hydroxyl-propyl-beta-cyclodextrin, Hydroxypropyl .beta.-cyclodextrin, Hydroxypropyl bcd, Hydroxypropyl betacyclodextrin, Hydroxypropyl betadex, Hydroxypropyl-bcyclodextrin, Hydroxypropylbetadex
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases9
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| Niemann-Pick disease, type C1 | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0009757 |
| Niemann-Pick disease type C | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0018982 |
| Alzheimer disease | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0004975 |
| cerebellar ataxia | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0000437 |
| decubitus ulcer | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0007067 |
| herpes labialis | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0043653 |
| ischemic stroke | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_1060198 |
| kidney failure | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0001106 |
| liver disorder | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005154 |
Source Open Targets
Trials14
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02418676 | Insulin Complexation With Hydroxypropyl-beta-cyclodextrin: Use of the Complex in Gel for Healing of Pressure Ulcers | Phase 1/2 | 15 | 2016-01-14 | hydroxypropyl-beta-cyclodextrin insulin complex | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT03471143 | Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C | Phase 1/2 | 4 | 2025-12-12 | 2-hydroxypropyl-beta-cyclodextrin | Its name | ClinicalTrials.gov |
| NCT03879655 | Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1 | Phase 2/3 | 2 | 2023-12-26 | 2-hydroxypropyl-beta-cyclodextrin | Its name | ClinicalTrials.gov |
| NCT04860960 | Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1 | Phase 3 | 94 | hydroxypropyl-beta-cyclodextrin | Its name | ClinicalTrials.gov | |
| NCT05607615 | A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease | Phase 2 | 90 | hydroxypropyl beta cyclodextrin | Its name | ClinicalTrials.gov | |
| NCT01812538 | A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects | Phase 1 | 70 | hydroxypropyl-β-cyclodextrin | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT00914745 | Place Controlled Study to Treat Recurrent Herpes Labialis. | Phase 2 | 40 | hydroxypropyl-beta-cyclodextrin | Its name | ClinicalTrials.gov | |
| NCT00805090 | Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects | Phase 1 | 37 | hydroxypropyl-β-cyclodextrin | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT01747135 | Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease | Phase 1 | 14 | hydroxypropyl beta cyclodextrin | Its name | ClinicalTrials.gov | |
| NCT02939547 | Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1) | Phase 1 | 13 | hydroxypropyl-beta-cyclodextrin | Its name | ClinicalTrials.gov |
1 to 10 of 14
See all 14 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials5
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL577294
GET https://conductscience.org/api/drugs/v1/CHEMBL577294/targets